{"id":"https://openalex.org/W1996137477","doi":"https://doi.org/10.1016/0024-3205(93)90588-t","title":"NE-100, a novel sigma receptor ligand: In vivo tests","display_name":"NE-100, a novel sigma receptor ligand: In vivo tests","publication_year":1993,"publication_date":"1993-01-01","ids":{"openalex":"https://openalex.org/W1996137477","doi":"https://doi.org/10.1016/0024-3205(93)90588-t","mag":"1996137477","pmid":"https://pubmed.ncbi.nlm.nih.gov/7901723"},"language":"en","primary_location":{"id":"doi:10.1016/0024-3205(93)90588-t","doi":"https://doi.org/10.1016/0024-3205(93)90588-t","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0024-3205(93)90588-t","pdf_url":null,"source":{"id":"https://openalex.org/S175775512","display_name":"Life Sciences","issn_l":"0024-3205","issn":["0024-3205","1879-0631"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Life Sciences","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110113221","display_name":"Shigeru Okuyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shigeru Okuyama","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","Research Center. Taisho Pharmaceutical Co., Ltd., 1\u2013403 Yoshino-cho. Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Research Center. Taisho Pharmaceutical Co., Ltd., 1\u2013403 Yoshino-cho. Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047573124","display_name":"Yasuko Imagawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasuko Imagawa","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shin-ichi Ogawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shin-ichi Ogawa","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112659639","display_name":"Hiroaki Araki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroaki Araki","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112580266","display_name":"Asako Ajima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Asako Ajima","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037866444","display_name":"Makoto Tanaka","orcid":"https://orcid.org/0000-0002-1826-3111","observed_orcids":["https://orcid.org/0000-0002-1826-3111"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Tanaka","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088760818","display_name":"Makoto Muramatsu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Muramatsu","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113554239","display_name":"Atsuro Nakazato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Atsuro Nakazato","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112610588","display_name":"Kazumasa Yamaguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275722","display_name":"Nihon Bioresearch Inc. (Japan)","ror":"https://ror.org/045v61422","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275722"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazumasa Yamaguchi","raw_affiliation_strings":["Nihon Bioresearch Center Inc. 6-104, Fukujucho, Majima, Hashima, Gifu 501-62, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nihon Bioresearch Center Inc. 6-104, Fukujucho, Majima, Hashima, Gifu 501-62, Japan","institution_ids":["https://openalex.org/I4405275722"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113446913","display_name":"Masumi Yoshida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275722","display_name":"Nihon Bioresearch Inc. (Japan)","ror":"https://ror.org/045v61422","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275722"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masumi Yoshida","raw_affiliation_strings":["Nihon Bioresearch Center Inc. 6-104, Fukujucho, Majima, Hashima, Gifu 501-62, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nihon Bioresearch Center Inc. 6-104, Fukujucho, Majima, Hashima, Gifu 501-62, Japan","institution_ids":["https://openalex.org/I4405275722"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113754408","display_name":"Susumu Otomo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Susumu Otomo","raw_affiliation_strings":["Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Center, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Ohmiya, Saitama 330, Japan","institution_ids":["https://openalex.org/I144245601"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3810,"currency":"USD","value_usd":3810},"apc_paid":null,"fwci":7.5166,"has_fulltext":false,"cited_by_count":119,"citation_normalized_percentile":{"value":0.98426284,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"53","issue":"18","first_page":"PL285","last_page":"PL290"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13047","display_name":"Pharmacological Receptor Mechanisms and Effects","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T13047","display_name":"Pharmacological Receptor Mechanisms and Effects","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ne-100","display_name":"NE-100","score":1.0},{"id":"https://openalex.org/keywords/sigma-receptor-ligands","display_name":"sigma receptor ligands","score":0.7919999957084656},{"id":"https://openalex.org/keywords/sigma-receptor-antagonists","display_name":"sigma receptor antagonists","score":0.8370000123977661},{"id":"https://openalex.org/keywords/antipsychotic-activity","display_name":"antipsychotic activity","score":0.9649999737739563},{"id":"https://openalex.org/keywords/catalepsy","display_name":"catalepsy","score":0.8669999837875366},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.6589999794960022},{"id":"https://openalex.org/keywords/stereotyped-behavior","display_name":"stereotypy","score":0.9470000267028809},{"id":"https://openalex.org/keywords/motor-side-effects","display_name":"motor side effects","score":0.7789999842643738},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.7402200102806091},{"id":"https://openalex.org/C2777052854","wikidata":"https://www.wikidata.org/wiki/Q7512419","display_name":"Sigma receptor","level":3,"score":0.7291846871376038},{"id":"https://openalex.org/C2780476085","wikidata":"https://www.wikidata.org/wiki/Q918193","display_name":"Catalepsy","level":4,"score":0.6870236992835999},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6020382642745972},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5844594836235046},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5492746829986572},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.4851873517036438},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.4839070737361908},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4541480243206024},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.4244294762611389},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.41707879304885864},{"id":"https://openalex.org/C103133801","wikidata":"https://www.wikidata.org/wiki/Q408572","display_name":"Sigma-1 receptor","level":4,"score":0.410508394241333},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.3521302342414856},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.3077353835105896},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2538341283798218},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.24038812518119812},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.15372785925865173},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.14232930541038513},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13578051328659058},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.11035898327827454},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.10738307237625122},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.07729437947273254}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000840","descriptor_name":"Anisoles","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000840","descriptor_name":"Anisoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001522","descriptor_name":"Behavior, Animal","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002375","descriptor_name":"Catalepsy","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008124","descriptor_name":"Locomotion","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010620","descriptor_name":"Phenazocine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010620","descriptor_name":"Phenazocine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011869","descriptor_name":"Radioligand Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011919","descriptor_name":"Rats, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013239","descriptor_name":"Stereotyped Behavior","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015259","descriptor_name":"Dopamine Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017480","descriptor_name":"Receptors, sigma","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0024-3205(93)90588-t","doi":"https://doi.org/10.1016/0024-3205(93)90588-t","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0024-3205(93)90588-t","pdf_url":null,"source":{"id":"https://openalex.org/S175775512","display_name":"Life Sciences","issn_l":"0024-3205","issn":["0024-3205","1879-0631"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Life Sciences","raw_type":"journal-article"},{"id":"pmid:7901723","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7901723","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Life sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W607389392","https://openalex.org/W1239326550","https://openalex.org/W1837308978","https://openalex.org/W1886668162","https://openalex.org/W1900414416","https://openalex.org/W1959599154","https://openalex.org/W1968248600","https://openalex.org/W1986807349","https://openalex.org/W2020678855","https://openalex.org/W2022649017","https://openalex.org/W2028531508","https://openalex.org/W2033959024","https://openalex.org/W2034340445","https://openalex.org/W2042535511","https://openalex.org/W2046516880","https://openalex.org/W2085483626","https://openalex.org/W2127749802","https://openalex.org/W2215141637","https://openalex.org/W2253312080","https://openalex.org/W2259599448","https://openalex.org/W4206587608"],"related_works":["https://openalex.org/W2399638292","https://openalex.org/W1979029439","https://openalex.org/W3046818045","https://openalex.org/W2073988385","https://openalex.org/W1984954364","https://openalex.org/W2413723205","https://openalex.org/W1966632536","https://openalex.org/W4256483912","https://openalex.org/W3102097934","https://openalex.org/W3041311641"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":7},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}